Cullinan Therapeutics, Inc. (CGEM)

Cullinan Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	-	18.94	-
Gross Profit	-	-	-	18.94	-
Selling, General & Admin	54.02	42.49	40.19	29.15	17.12
Research & Development	142.9	148.16	91.95	57.75	43.21
Operating Expenses	196.92	190.65	132.14	86.9	60.34
Operating Income	-196.92	-190.65	-132.14	-67.95	-60.34
Interest & Investment Income	29.66	21.63	6.61	0.48	0.89
Other Non Operating Income (Expenses)	-0.2	0.24	0.06	-0.01	-0.01
EBT Excluding Unusual Items	-167.46	-168.78	-125.47	-67.49	-59.46
Gain (Loss) on Sale of Assets	-	-	276.79	-	-
Asset Writedown	-	-0.44	-	-	-
Pretax Income	-167.46	-169.22	151.32	-67.49	-59.46
Income Tax Expense	0.12	-14.12	42.12	-	-
Earnings From Continuing Operations	-167.58	-155.1	109.2	-67.49	-59.46
Minority Interest in Earnings	0.19	1.94	2.02	1.92	7.66
Net Income	-167.38	-153.16	111.21	-65.57	-51.8
Net Income to Common	-167.38	-153.16	111.21	-65.57	-51.8
Shares Outstanding (Basic)	54	42	45	43	20
Shares Outstanding (Diluted)	54	42	47	43	20
Shares Change (YoY)	29.41%	-10.91%	8.27%	116.61%	2088.17%
EPS (Basic)	-3.11	-3.69	2.46	-1.52	-2.60
EPS (Diluted)	-3.11	-3.69	2.38	-1.52	-2.60
Free Cash Flow	-145.3	-134.48	-127.8	-43.43	-29.78
Free Cash Flow Per Share	-2.70	-3.24	-2.74	-1.01	-1.50
Gross Margin	-	-	-	100.00%	-
Operating Margin	-	-	-	-358.73%	-
Profit Margin	-	-	-	-346.14%	-
Free Cash Flow Margin	-	-	-	-229.28%	-
EBITDA	-196.61	-190.34	-132.04	-67.9	-60.27
D&A For EBITDA	0.31	0.31	0.09	0.05	0.06
EBIT	-196.92	-190.65	-132.14	-67.95	-60.34
Effective Tax Rate	-	-	27.84%	-	-

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q